Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

Shanghai Stock Exchange 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBT Margin for the year ending December 31, 2023: -7.50%

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBT Margin is -7.50% for the year ending December 31, 2023, a -123.48% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBT Margin for the year ending December 31, 2022 was 31.93%, a -2.22% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBT Margin for the year ending December 31, 2021 was 32.65%, a 4.06% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBT Margin for the year ending December 31, 2020 was 31.38%, a 13.90% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBT Margin for the year ending December 31, 2019 was 27.55%, a 0.15% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Shanghai Stock Exchange: 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

CEO	Ms. Wu Guiping
IPO Date	July 19, 2017
Location	China
Headquarters	1/16 Nanjing Jiangbei New
Employees	1,451
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years